Interact with experts and peers.

Recent Posts

10 of 29 Shown
  • Are New HCV Therapies Ready for Use in Transplant Patients?

    Paul Y. Kwo MD - 7/10/2014 3 comments / Last Comment: 8/21/2014
    Paul Y. Kwo, MD, introduces some of the topics that will be discussed in an upcoming symposium in San Francisco.
  • Genotype 1 HCV–Infected Cirrhotic Patients: Still Hard to Treat?

    Mark S. Sulkowski MD - 6/27/2014 4 comments / Last Comment: 7/29/2014
    After a long wait, the great majority of cirrhotic patients now has a realistic chance of achieving HCV cure.
  • My Approach to Identifying Treatment Candidates and Maintaining Patients on Long-term HBV Therapy

    Anna S. F. Lok MD - 6/19/2014 8 comments / Last Comment: 8/13/2014
    I find it helpful to discuss the impact of treatment on liver fibrosis/cirrhosis and hepatocellular carcinoma with patients, which motivates some to initiate and adhere to their long-term treatment.
  • Post-EASL Update: What Is the Role of Treatment Guidelines in the Current HCV Era?

    Jordan J. Feld MD, MPH - 5/22/2014 8 comments / Last Comment: 8/26/2014
    With the new era of HCV therapies comes a new era in clinical guidelines; although there is certainly overlap, the major guidelines serve different but important roles.
  • Post-EASL Update: How I Manage HCV Patients for Whom First-Generation Protease Inhibitors Failed

    Stefan Zeuzem MD - 5/19/2014 7 comments / Last Comment: 8/31/2014
    Following new data from the ION-2 study reported at EASL 2014, options for retreatment of patients with previous PI failure appear much improved.
  • Treating HBV Patients With Cirrhosis: The Need for Vigilant HCC Screening

    Maria Buti MD - 5/14/2014 5 comments / Last Comment: 8/25/2014
    Antiviral therapy can dramatically improve liver histology, even in cirrhotic patients, but it remains critical to screen patients with suppressed viral load for hepatocellular carcinoma.
  • Post-EASL Update: Reconsidering Whether to Treat Genotype 1 HCV Patients or Wait for All-Oral Therapy

    Paul Y. Kwo MD - 5/12/2014 4 comments / Last Comment: 8/23/2014
    Following the presentation of phase III data on new all-oral regimens for genotype 1 HCV at EASL, which patients might wait for the approval of new therapies and which should be treated now?
  • Appraising the 2014 AASLD/IDSA Guidelines on HCV Testing and Treatment

    Nezam H. Afdhal MD, FRCPI - 4/22/2014 3 comments / Last Comment: 7/25/2014
    Nezam H. Afdhal, MD, FRCPI, analyzes new guidelines on HCV testing and treatment from the AASLD and IDSA and provides his own interpretation of the supporting data.
  • Post-CROI Update: How I Manage HIV/HCV-Coinfected Patients

    Jürgen K. Rockstroh MD - 4/9/2014 3 comments / Last Comment: 6/20/2014
    How should HIV treaters apply the latest HCV study results and guidelines to the management of coinfected patients?
  • Enter the Nonspecialist: Will Evolving Hepatitis C Therapies Reduce the Need for Specialized Care?

    Graham R. Foster FRCP, PhD - 10/8/2013 20 comments / Last Comment: 2/5/2014
    As therapeutic options for hepatitis C therapy evolve with reduced dosing requirements and improved adverse event profiles, the need for specialist care will diminish.
10 of 29 Shown
Show 10 More